Customize your JAMA Network experience by selecting one or more topics from the list below.
JAMA Psychiatry experienced both stability and evolution in 2019. We celebrated the 100th anniversary of the Archives of Neurology and Psychiatry, which I discussed recently.1 In important ways, the history of our journal mirrors the history of American psychiatry: we benefit from the traditions developed over 100 years but must face the ongoing challenge of alleviating the heavy and rising burden of psychiatric disorders.
Our editorial team remains in place with Martin Paulus, MD, serving as Deputy Editor, H. Blair Simpson, MD, PhD, as Associate Editor, and John Torous, MD, MS, as Web Editor. Sara DiBari remains the journal’s Editorial Manager and most critical support. To this team, we have added an expanded group of Statistical Editors who regularly review articles for the journal and provide editorial input. Psychiatric science is broad and diverse, and no one biostatistician can have expertise in all the domains we cover, from clinical trials to epidemiology and neuroimaging. Therefore, we rely on a group of individuals with complementary expertise within biostatistics to help us evaluate as many of the articles we ultimately publish as possible. I am thankful for their contributions.
The journal continues to receive ever-growing numbers of submissions, with the number of manuscripts received in 2019 surpassing the previous all-time high mark (Table).2-4 We make it a priority to handle all manuscripts in a timely and responsive manner despite this larger volume. Those manuscripts we decide not to pursue, we reject with a median turnaround time of 2 days so that authors can submit their work elsewhere in quick succession. We only send a small percentage of manuscripts out for peer review, and in 2019, we ultimately published 8% of all submitted research manuscripts. We also strive to maintain a fast pace for manuscripts sent out for peer review; last year it took 32 days from receipt to first decision for those articles. This allows us to make timely editorial decisions and rapidly publish accepted manuscripts. I am proud of our team for maintaining these high standards, all of which serve to improve the experience of our authors who submit their best work to JAMA Psychiatry.
Every day, I am humbled by the hard work, expertise, intelligence, and collegiality of experts across the globe who review manuscripts for the journal. It inspires me to do just as good a job as editor, which is what our reviewers deserve. Peer review is laborious and complex, but even in this preprint server era, I am confident that it greatly improves the quality of the articles we publish. I thank all our peer reviewers for their contribution.5
JAMA Psychiatry remains a leading journal in our field. In 2019, our impact factor was 15.9. We have more than 54 000 followers on Twitter and Facebook and more than 64 000 individual recipients of our weekly electronic table of contents. In 2019, we had more than 5.2 million full-text/PDF articles downloaded from our website. Articles we publish are also influential in news and social media, as indicated by Altmetric scores. The JAMA Psychiatry articles from 2019 with the highest Altmetric score are listed in the Table.2-4 One of these articles also made it onto the list of top 100 scientific articles with the highest Altmetric scores for 2019.6
JAMA Psychiatry has a deserved reputation for publishing rigorous and sophisticated scientific research, but it also caters to a broad clinical audience. In recent years, we have published more and more Viewpoints, Clinical Challenges, clinical trial reports, and other articles of interest to mental health clinicians. In 2019, we added a new article type called JAMA Network Insights to this growing repertoire. I recently reviewed this article type.7 We have already published several such articles and plan to publish them on an ongoing basis. We welcome inquiries and submissions regarding any of these article types from interested authors. Our goal is to publish a journal that disseminates the best new original research in psychiatry while also providing useful clinical updates, both for a scientific and a general psychiatry audience.
The past year brought more news about the worsening public health impact of psychiatric and substance use disorders. Life expectancy in the US is shortening for the first time in decades8 partly due to deaths of despair, ie, excess deaths attributable to drug and alcohol use or suicide. I regularly meet patients and families grappling with devastating psychiatric disorders where available treatments are not enough to improve their quality of life, and I know many of you do as well. Psychiatry is at the frontlines of the battle to improve the lives of our patients and their families, and we must redouble our efforts to deliver on this hope. JAMA Psychiatry will continue to do its part in the new decade.
Corresponding Author: Dost Öngür, MD, PhD, McLean Hospital, Harvard Medical School, 115 Mill St, Mailstop #108, Room AB320, Belmont, MA 02478 (email@example.com).
Published Online: March 25, 2020. doi:10.1001/jamapsychiatry.2020.0102
Conflict of Interest Disclosures: None reported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Öngür D. JAMA Psychiatry—The Year in Review, 2019. JAMA Psychiatry. 2020;77(5):451–452. doi:10.1001/jamapsychiatry.2020.0102
Coronavirus Resource Center
Create a personal account or sign in to: